Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment

Immunoglobulin (Ig)G replacement with intravenous or subcutaneous immunoglobulins is a lifelong substitutive therapy in patients with primary antibody deficiencies (PADs). Hemolysis after immunoglobulin therapy was described in patients receiving high immunoglobulin dosages. The issue of hemolysis after immunoglobulin administration at replacement doses has been considered of little clinical significance.

[1]  M. Murphy,et al.  Intravenous immunoglobulin‐induced haemolysis: a case report and review of the literature , 2014, Transfusion medicine.

[2]  J. Lipton,et al.  Acute hemolysis after intravenous immunoglobulin amid host factors of ABO‐mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes , 2014, Transfusion.

[3]  R. Schmidt,et al.  Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients , 2013, Clinical and experimental immunology.

[4]  C. Cunningham-Rundles.  The many faces of common variable immunodeficiency. , 2012, Hematology. American Society of Hematology. Education Program.

[5]  H. Schroeder,et al.  Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients , 2012, Infection.

[6]  Sofya Pintova,et al.  IVIG--a hemolytic culprit. , 2012, The New England journal of medicine.

[7]  M. Akhtari,et al.  Hematologic toxicities associated with intravenous immunoglobulin therapy. , 2011, International immunopharmacology.

[8]  M. Werner,et al.  T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. , 2011, Blood.

[9]  C. Cunningham-Rundles.  Key aspects for successful immunoglobulin therapy of primary immunodeficiencies , 2011, Clinical and experimental immunology.

[10]  J. Zimring,et al.  Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. , 2010, Blood.

[11]  Kathleen C. Williams,et al.  Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. , 2010, Clinical immunology.

[12]  A. Heath,et al.  International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti‐A and anti‐B in normal intravenous immunoglobulin products , 2009, Vox sanguinis.

[13]  C. Galambos.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes , 2009 .

[14]  C. Horkan,et al.  Rapid Encephalopathy Associated with Anti-D Immune Globulin Treatment for Idiopathic Thrombocytopenic Purpura , 2008, Acta Haematologica.

[15]  R. Padmore,et al.  Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.

[16]  L. Parise,et al.  Cytokines and plasma factors in sickle cell disease , 2007, Current opinion in hematology.

[17]  A. Plebani,et al.  Long-Term Follow-Up and Outcome of a Large Cohort of Patients with Common Variable Immunodeficiency , 2007, Journal of Clinical Immunology.

[18]  A. Heath,et al.  International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[19]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[20]  R. Thorpe,et al.  Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[21]  R. Thorpe,et al.  Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti‐Rh D activity , 2003, Vox sanguinis.

[22]  L. Notarangelo,et al.  Diagnostic Criteria for Primary Immunodeficiencies , 1999 .

[23]  Y. Shoenfeld,et al.  In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. , 1999, Journal of autoimmunity.

[24]  L. Notarangelo,et al.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). , 1999, Clinical immunology.

[25]  Y. Naot,et al.  Immune complex‐like moieties in immunoglobulin for intravenous use (IVIg) bind complement and enhance phagocytosis of human erythrocytes , 1998, Clinical and experimental immunology.

[26]  F. Rodeghiero,et al.  A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. , 1992, Haematologica.